Use of zoledronic acid to prepare drug treating fatty liver disease
US10391109B2 · kind B2 · utility
0Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 30, 2016 |
| Grant date | Aug 27, 2019 |
| Priority date | — |
| Expiry date | Jun 30, 2036 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P1/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method for treating fatty liver disease in a patient in need thereof, including a step of administering an effective amount of zoledronic acid. The fatty liver disease includes fatty liver disease caused by foodborne and hereditary factors, in particular non-alcoholic fatty liver. A dosage form of the zoledronic acid is an injection, a solution, a tablet, or a capsule.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.